Navigation Links
Historic Breakthrough in Fighting Children's Batten Disease as China Stem Cells Give New Lease on Life to 6 Year Old California Boy
Date:1/30/2008

BEIJING, Jan. 30 /Xinhua-PRNewswire/ -- Tiantan Puhua Hospital Stem Cells Center ( http://www.stemcellspuhua.com ), the worldwide leader in using stem cells to effectively treat Parkinson's and other neurological diseases, announced another historic first in successfully using stem cells to improve and potentially prolong the life of 6 year old California native Blake Dell'Aringa. Blake was a normal, happy toddler until last year when diagnosed in America with what has been widely thought an untreatable genetic disorder occurring primarily in children called "Batten Disease". Due to a missing gene, the disease causes sudden, rapid degeneration of the nervous system and always ends in premature fatality, often between the ages of 6 and 12. After undergoing Tiantan Puhua's comprehensive stem cell therapy program in Beijing, Blake's family is now reporting a significant reversal in the recent swift deterioration of Blake's motor skills, giving real hope that he will live long enough for a scientific cure to be found. More on Blake can be found at http://www.stemcellspuhua.com/s71.html .

Blake's mother Dawn said, "Our world was just rocked when Blake was diagnosed with Batten Disease. Now, every second of his life is meaningful to us. Going all the way to China wasn't our first choice, but it was almost our only choice and definitely the right one as Blake has had clear improvement since he's returned. Every day he's stronger and stronger than before. Tiantan Puhua has given Blake real hope."

Blake's parents decided to bring him to Beijing after first being allowed to participate, but then later rejected just days before commencing treatment, in one of America's only federally authorized stem cell trials in the State of Oregon. As is often the case in the West, patients like Blake can be blocked or delayed for political reason
'/>"/>

SOURCE Tiantan Puhua Hospital Stem Cells Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
2. Breakthrough Opportunity for Improving Patient Health
3. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
4. The Wisconsin Heart Hospital Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
5. Panacea Pharmaceuticals Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazines Ten Biggest Medical Breakthroughs of 2007
6. Stem Cell Breakthrough Could End Human Embryonic Experimentation
7. Discovery Institute Bioethicist Lauds Breakthrough in Stem Cells Research that Eliminates Need for Human Cloning
8. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
9. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
10. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
11. Breakthrough research identifies how cells from pigs may cure diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
(Date:5/21/2015)... of Prussia, PA (PRWEB) May 21, 2015 ... Julia O’Neill has joined the firm as senior statistician ... than 30 years of experience in the management and ... vaccines, biologics, pharmaceutical and chemical industries. , “We’re delighted ... our longstanding capabilities in data analytics,” said Dr. Philippe ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has ... Market Outlook 2020 " report to their offering. ... regenerative medicine is expected to have huge marketing potential. ... in the growth of deregulated organs. Several therapeutic molecules ... to form new tissue or sometimes organ transplant is ...
Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... , DALLAS, July 23 ... S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) ... collecting data from a post approval study of MuGard in head and neck cancer ... a multi-center study expected to enroll a total of 280 patients, patients are provided ...
... , , ST. LOUIS, July ... Science and High Technology company, reported second quarter 2009 diluted EPS ... For the six months ended June 30, 2009, reported diluted ... the first six months of 2008. Excluding the negative impact ...
... , , SEATTLE, July 23 ... today announced the pricing of an underwritten public offering of 29,332,107 ... 7,333,027 shares of its common stock at a price to the ... purchase 0.25 shares of common stock, for gross proceeds of approximately ...
Cached Biology Technology:MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 2Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 4Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 5Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 6Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 7Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 8Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 9Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 10Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 11Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 12Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 13Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 14Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 15Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 16Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 17Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Today, the country,s leading health technology company, ... $15 million in new funding. This extension funding, led ... Ventures, brings Practice Fusion,s Series D funding to $85 ... million. The round was co-led by Longitude Capital, a ...
... (Dec. 9, 2013) For nearly half a century, ... ocular drug delivery that may someday replace eye drops, ... challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School ... Institute of Technology are one step closer to an ...
... gene that drives the development of tumours in over one ... time that the gene CUX1 has been broadly linked to ... deactivated, a biological pathway is activated that increases tumour growth. ... in the clinic and are in development thus highlighting a ...
Cached Biology News:Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 3Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month 2Gene promotes 1 in 100 of tumors 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
RABBIT ANTI PARATHION...
Biology Products: